5.0 Out Of 69 Reviews
RANKED #1 IN DFW, SOUTHERN OKLAHOMA, AND CALIFORNIA FOR MOBILE IV THERAPY
5.0 Out Of 69 Reviews
RANKED #1 IN DFW, SOUTHERN OKLAHOMA, AND CALIFORNIA FOR MOBILE IV THERAPY
Tesamorelin is a growth hormone releasing factor analog prescribed as a 3 mg/mL injection and used when the metabolic target is specific, particularly visceral fat. It is prescription only. Bee WellSM dispenses it after a licensed provider reviews your history and labs.
| Specification | Detail |
|---|---|
| Strength | 3 mg/mL |
| Presentation | 5 mL vial |
| Route | Subcutaneous injection |
| Category | Performance & Metabolic |
| Availability | Prescription only, after provider consultation |
Strengths may vary. Final strength, dose, and schedule are determined by your provider at consultation.
Tesamorelin prompts growth hormone release, and it is distinctive in the set because its relationship to visceral fat has been studied directly rather than inferred from general growth hormone activity.
Visceral fat sits around the organs rather than under the skin, and it behaves differently from subcutaneous fat metabolically. That difference is why a targeted option exists at all.
Adults whose provider has identified visceral fat or a specific metabolic marker as the target, usually with labs already in hand.
Active malignancy, pregnancy or breastfeeding, and certain pituitary conditions rule it out. Compounded tesamorelin is not Egrifta and is not prescribed for the approved product’s indication.
Peptides are easy to buy online and hard to buy safely. Bee Well℠ runs every peptide protocol through a licensed provider who evaluates whether it fits your situation, and sources through verified pharmacy partners rather than research suppliers.
Bee Well℠ is LegitScript certified, which means the licensing, prescribing practices, and privacy standards behind this service have been independently verified. Telehealth consultations are available across the service area, with mobile visits in the DFW metroplex including Denton, Fort Worth, and Frisco.
A growth hormone releasing factor analog used in protocols targeting visceral fat and metabolic markers.
No. Egrifta is the FDA-approved product with its own approved indication. Compounded tesamorelin is a different product and is not prescribed for that indication.
Fat stored around the internal organs rather than under the skin. It behaves differently from subcutaneous fat, which is why it is targeted separately.
In most cases yes. Your provider determines which panel applies at your consult.
Results vary from person to person and depend on your starting point, your protocol, and how consistently you follow it. Some patients notice changes within a few weeks. Others take longer, or see little change at all. No outcome is guaranteed, and your provider will set realistic expectations at your consultation.
Any prescribed product can cause side effects. Which ones are relevant to you depends on your health history, your current medications, and the protocol your provider sets. Your provider will review the full profile with you at consultation and tell you what to watch for.
Yes. Tesamorelin Injection is prescription only. Bee Well℠ requires a consultation with a licensed provider, available by telehealth, before anything is prescribed or dispensed. Availability also depends on the state you are in.
As subcutaneous injection at 3 mg/mL from a 5 ml vial. The exact method, dose, and schedule depend on the protocol your provider sets.
A consultation is the only way to know whether Tesamorelin Injection fits your situation. Telehealth appointments are available across the service area.
Disclaimer: Strengths may vary, and results differ from person to person. Information on this page is provided for informational purposes and is not medical advice. Consult a licensed provider before use.
Availability and permitted use vary by state. A telehealth consultation with a licensed provider is required before any peptide is prescribed or dispensed, and some products may not be available in all locations.